Conditions: Psoriatic Arthritis
Keywords: Psoriatic arthritis PsA ACR CASPAR
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 606
Healthy volunteers: no

Brief summary:
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.

Detailed description:

Arms:
arm 1: Secukinumab (75mg) arm 2: Secukinumab (150 mg) arm 3: None

Interventions: intervention 1: Secukinumab (75 mg) intervention 2: Secukinumab (150 mg) intervention 3: Placebo Comparator
Intervention descriptions: intervention 1: Secukinumab (75 mg) intervention 2: Secukinumab (150 mg) intervention 3: Placebo Comparator

Protocol document: